Roger Dmochowski appointed as Versameb’s chief medical officer
Versameb AB has announced the appointment of Professor Roger Dmochowski as chief medical officer.
Dmochowski is a renowned researcher and urologist, as well as being a leading, published academic in the urologic and incontinence fields. Previously Dmochowski has served as part of the US Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and was involved in the FDA’s guidelines for regenerative medicine in urology. He is also a trustee and past president of the American Board of Urology and a Fellow of the American College of Surgeons, the American Urological Association and the International Continence Society.
Dmochowski has worked with Versameb since August 2021, having previously worked as part of the Scientific Advisory Board.
Dr Klaas Zuideveld, chief executive officer of Versameb, stated: “Roger joins Versameb at an important time of growth and development and his appointment marks a significant milestone as we advance towards clinical development with our lead candidate, VMB-100, for the treatment of stress urinary incontinence (SUI). Roger’s unrivalled experience in the field of urology will be instrumental as we look to transform the treatment landscape for SUI.”
Commenting on his appointment, Dmochowski added: “I am eager to contribute my expertise to advance VMB-100 which has demonstrated functional recovery and tissue regeneration in preclinical models for the unmet medical need of SUI. SUI is a very common bladder problem which affects one in three women at some point in their lives with no current drug treatment approved that restores function and has a lasting effect. VMB-100 has the potential to be a game changer for women’s health and wellbeing.”
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
After more than two decades at the head of the company, it has emerged that …